Approximately 250,000 doses of the SK bioscience’s Influenza vaccine are exported to Asia including Thailand, Malaysia

SK bioscience plans to participate in the international bidding market

SK bioscience announced on the 17th that the company will initiate exporting its homegrown cell culture-based influenza vaccine, ´SKYCellflu®.’

The initial shipment is expected ahead of the flu vaccination season with about 250,000 doses to Asian countries that do not have their own influenza vaccines such as Thailand, Malaysia, Singapore, and Mongolia.

Starting with this export, SK bioscience is planning to expand its overseas presence by participating in the World Health Organization (WHO) international bidding next year. SKYCellflu is the world´s first quadrivalent cell culture-based influenza vaccine to receive WHO PQ (Pre-qualification) in April. Vaccines that have obtained PQ certification will be eligible to participate in international bids organized by UN agencies such as UNICEF and Pan-American Health Organization (PAHO).

SKYCellflu is the only cell culture-based influenza vaccine in South Korea and is produced through an incubator, requiring no administration of antibiotics or preservatives.

SKYCellflu has recorded sales of more than 20 million doses in its fifth year in Korea alone.

Jaeyong Ahn, CEO of SK bioscience said, "Our influenza vaccine developed with domestic technology is starting to be exported with a significant volume. We are going to create a global vaccine brand that will contribute to human health worldwide.”